Supplemental Annuity Collective Trust (SACT) of New Jersey’s Xenon Pharmaceuticals XENE Stock Holding History

Supplemental Annuity Collective Trust (SACT) of New Jersey’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,000	Closed	-$493K	–	368
2025 Q4	$493K	Hold	11,000	–	–	0.13%	154
2025 Q3	$442K	Hold	11,000	–	–	0.12%	163
2025 Q2	$344K	Hold	11,000	–	–	0.1%	174
2025 Q1	$369K	Hold	11,000	–	–	0.12%	171
2024 Q4	$431K	Hold	11,000	–	–	0.13%	164
2024 Q3	$433K	Hold	11,000	–	–	0.13%	168
2024 Q2	$429K	Hold	11,000	–	–	0.13%	159
2024 Q1	$474K	Hold	11,000	–	–	0.15%	155
2023 Q4	$507K	Hold	11,000	–	–	0.18%	138
2023 Q3	$376K	Hold	11,000	–	–	0.14%	161
2023 Q2	$424K	Hold	11,000	–	–	0.15%	155
2023 Q1	$394K	Hold	11,000	–	–	0.15%	157
2022 Q4	$434K	Hold	11,000	–	–	0.18%	149
2022 Q3	$397K	Hold	11,000	–	–	0.17%	154
2022 Q2	$335K	Hold	11,000	–	–	0.13%	173
2022 Q1	$336K	Hold	11,000	–	–	0.11%	196
2021 Q4	$344K	Hold	11,000	–	–	0.11%	194
2021 Q3	$168K	Hold	11,000	–	–	0.06%	220
2021 Q2	$205K	Hold	11,000	–	–	0.07%	216
2021 Q1	$197K	Hold	11,000	–	–	0.07%	217
2020 Q4	$169K	Hold	11,000	–	–	0.06%	211
2020 Q3	$122K	Hold	11,000	–	–	0.05%	211
2020 Q2	$138K	Hold	11,000	–	–	0.06%	210
2020 Q1	$125K	Hold	11,000	–	–	0.07%	197
2019 Q4	$144K	Hold	11,000	–	–	0.06%	225
2019 Q3	$99K	Buy	+11,000	New	+$104K	0.05%	219

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Supplemental Annuity Collective Trust (SACT) of New Jersey's XENE Position: Q1 2026 in Review

Supplemental Annuity Collective Trust (SACT) of New Jersey sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 11,000 shares — an estimated $493K sold.

Supplemental Annuity Collective Trust (SACT) of New Jersey first reported a position in XENE in Q3 2019 and held it in 26 quarters. The position peaked at $507K in Q4 2023. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Supplemental Annuity Collective Trust (SACT) of New Jersey reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Supplemental Annuity Collective Trust (SACT) of New Jersey sold 11,000 Xenon Pharmaceuticals shares in Q1 2026, an estimated $493K.
Supplemental Annuity Collective Trust (SACT) of New Jersey first reported a position in Xenon Pharmaceuticals in Q3 2019 and held it in 26 quarters.
Supplemental Annuity Collective Trust (SACT) of New Jersey's Xenon Pharmaceuticals position peaked at $507K in Q4 2023.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Supplemental Annuity Collective Trust (SACT) of New Jersey's 13F filing for Q1 2026, filed 1 May 2026.